| Literature DB >> 32923936 |
Eleni Christodoulou1, Georgios Batsos1, Petros Galanis2, Christos Kalogeropoulos1, Andreas Katsanos1, Yannis Alamanos3, Maria Stefaniotou1.
Abstract
PURPOSE: The aim of this study is to analyze the effect of internal limiting membrane peeling in removal of idiopathic epiretinal membranes through meta-analysis.Entities:
Keywords: epiretinal membrane; internal limiting membrane; macular pucker; peeling
Year: 2020 PMID: 32923936 PMCID: PMC7446271 DOI: 10.1177/2515841420927133
Source DB: PubMed Journal: Ther Adv Ophthalmol ISSN: 2515-8414
Figure 1.PRISMA Flow Diagram.
Data extracted regarding BCVA in logMAR.
| Study | PMID | Year | Method | Patients | Preoperative BCVA | SD preoperative BCVA | BCVA 6 months or longer | SD BCVA 6 months or longer | Change | SD change | SE change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lim and colleagues[ | 20,689,783 | 2010 | With ILM peel | 18 | 0.43 | 0.27 | 0.22 | 0.29 | −0.21 | 0.280535 | 0.066123 |
| Obata and colleagues[ | 27,760,434 | 2017 | Without ILM peel | 61 | 0.32 | 0.26 | 0.05 | 0.18 | −0.27 | 0.230651 | 0.029532 |
| Deltour and colleagues[ | 27,429,376 | 2017 | With ILM peel (actively) | 22 | 0.34 | 0.12 | 0.15 | 0.23 | −0.19 | 0.199249 | 0.04248 |
| Deltour and colleagues[ | 27,429,376 | 2017 | With ILM peel (spontaneously) | 10 | 0.25 | 0.18 | 0.1 | 0.05 | −0.15 | 0.160935 | 0.050892 |
| Shimada and colleagues[ | 19,427,701 | 2009 | With ILM peel (no stain) | 46 | 0.57 | 0.31 | 0.29 | 0.28 | −0.28 | 0.296142 | 0.043664 |
| Shimada and colleagues[ | 19,427,701 | 2009 | With ILM peel (TA) | 42 | 0.56 | 0.31 | 0.28 | 0.3 | −0.28 | 0.305123 | 0.047081 |
| Shimada and colleagues[ | 19,427,701 | 2009 | With ILM peel (BBG) | 54 | 0.59 | 0.36 | 0.23 | 0.26 | −0.36 | 0.32187 | 0.043801 |
| Kwok and colleagues[ | 16,033,350 | 2005 | Without ILM peel | 17 | 0.96 | 0.18 | 0.65 | 0.32 | −0.31 | 0.277849 | 0.067388 |
| Mayer and colleagues[ | 26,421,182 | 2015 | With ILM peel | 42 | 0.60 | 0.20 | 0.2 | 0.2 | −0.4 | 0.2 | 0.030861 |
| Tari and colleagues[ | 17,558,317 | 2007 | With ILM peel | 10 | 0.40 | 0.11 | 0.2 | 0.14 | −0.2 | 0.131149 | 0.043716 |
| Pournaras and colleagues[ | 21,469,962 | 2011 | Without ILM peel | 15 | 0.48 | 0.22 | 0.37 | 0.42 | −0.11 | 0.363868 | 0.09395 |
| Ripandelli and colleagues[ | 25,158,943 | 2015 | With ILM peel | 30 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ripandelli and colleagues[ | 25,158,943 | 2015 | Without ILM peel | 30 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Lee and colleagues[ | 20,401,561 | 2010 | Without ILM peel | 19 | 0.67 | 0.34 | 0.32 | 0.23 | −0.35 | 0.3005 | 0.068939 |
| Ahn and colleagues[ | 23,743,638 | 2014 | Without ILM peel | 69 | 0.31 | 0.21 | 0.11 | 0.12 | −0.2 | 0.182483 | 0.021968 |
| Machado and colleagues[ | 25,932,723 | 2015 | With ILM peel | 31 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Tranos and colleagues[ | 28,045,374 | 2017 | Without ILM peel | 52 | 0.55 | 0.05 | n/a | n/a | −0.31 | 0.23 | 0.031895 |
| Tranos and colleagues[ | 28,045,374 | 2017 | With ILM peel | 50 | 0.50 | 0.04 | n/a | n/a | −0.3 | 0.24 | 0.033941 |
| De Novelli and colleagues[ | 29,215,533 | 2019 | Without ILM peel | 35 | 0.67 | 0.29 | 0.27 | 0.25 | −0.4 | 0.272213 | 0.046012 |
| De Novelli and colleagues[ | 29,215,533 | 2019 | With ILM peel | 28 | 0.63 | 0.31 | 0.43 | 0.43 | −0.2 | 0.384318 | 0.072629 |
| Kumar and colleagues[ | 26,659,009 | 2016 | With ILM peel | 44 | 0.65 | 0.15 | 0.24 | 0.13 | −0.41 | 0.141067 | 0.021267 |
| Manousaridis and colleagues[ | 26,499,510 | 2016 | With ILM peel | 20 | 0.6 | 0.2 | 0.3 | 0.1 | −0.3 | 0.173205 | 0.03873 |
BCVA, best-corrected visual acuity; ILM, internal limiting membrane; TA: triamcinolone; BBG: brilliant blue G; PMID: PubMed IDentifier.
Data extracted regarding CFT in μm.
| Study | PMID | Year | Method | Patients | Preoperative CFT | SD preoperative CFT | CFT 6 months or longer | SD CFT 6 months or longer | Change | SD change | SE change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lim and colleagues.[ | 20,689,783 | 2010 | With ILM peel | 18 | 485 | 95.6 | 314.5 | 69.5 | −170.5 | 85.59 | 20.17 |
| Obata and colleagues.[ | 27,760,434 | 2017 | Without ILM peel | 61 | 463.6 | 80.7 | 369 | 60.2 | −94.6 | 72.65 | 9.30 |
| Deltour and colleagues.[ | 27,429,376 | 2017 | With ILM peel (actively) | 22 | 465.36 | 70.4 | 365.5 | 43.6 | −99.86 | 61.54 | 13.12 |
| Deltour and colleagues.[ | 27,429,376 | 2017 | With ILM peel (spontaneously) | 10 | 476.5 | 72.7 | 414.3 | 45.2 | −62.2 | 63.58 | 20.11 |
| Shimada and colleagues[ | 19,427,701 | 2009 | With ILM peel (no stain) | 46 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Shimada and colleagues[ | 19,427,701 | 2009 | With ILM peel (TA) | 42 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Shimada and colleagues[ | 19,427,701 | 2009 | With ILM peel (BBG) | 54 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Kwok and colleagues[ | 16,033,350 | 2005 | Without ILM peel | 17 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Mayer and colleagues.[ | 26,421,182 | 2015 | With ILM peel | 42 | 455.7 | 104.3 | 332.3 | 55.1 | −123.4 | 90.37 | 13.95 |
| Tari and colleagues[ | 17,558,317 | 2007 | With ILM peel | 9 | 433.33 | 75.51 | 330.67 | 32,29 | −102.66 | 65.62 | 21.87 |
| Pournaras and colleagues[ | 21,469,962 | 2011 | Without ILM peel | 15 | n/a | n/a | 268.0 | 98.0 | n/a | n/a | n/a |
| Ripandelli and colleagues[ | 25,158,943 | 2015 | With ILM peel | 30 | 464.2 | 89.2 | 376.9 | 45.12 | −87.3 | 77.25 | 14.10 |
| Ripandelli and colleagues[ | 25,158,943 | 2015 | Without ILM peel | 30 | 473.8 | 75.7 | 351.03 | 40.24 | −122.77 | 65.60 | 11.98 |
| Lee and colleagues[ | 20,401,561 | 2010 | Without ILM peel | 19 | 398.42 | 95.34 | 282.53 | 95.71 | −115.89 | 95.52 | 21.92 |
| Ahn and colleagues[ | 23,743,638 | 2014 | Without ILM peel | 69 | 445 | 99.3 | 356 | 58.9 | −89 | 86.49 | 10.41 |
| Machado and colleagues[ | 25,932,723 | 2015 | With ILM peel | 31 | 451.9 | 90.36 | 221.94 | 35.04 | −229.96 | 78.91 | 14.17 |
| Tranos and colleagues[ | 28,045,374 | 2017 | Without ILM peel | 52 | 540 | 113 | n/a | n/a | −134 | 93 | 12.90 |
| Tranos and colleagues[ | 28,045,374 | 2017 | With ILM peel | 50 | 512 | 120 | n/a | n/a | −125 | 103 | 14.57 |
| De Novelli and colleagues[ | 29,215,533 | 2019 | Without ILM peel | 35 | 486 | 125 | 377 | 82.5 | −109 | 110.09 | 18.61 |
| De Novelli and colleagues[ | 29,215,533 | 2019 | With ILM peel | 28 | 475 | 117 | 388 | 69.2 | −87 | 101.89 | 19.26 |
| Kumar and colleagues[ | 26,659,009 | 2016 | With ILM peel | 44 | 436.72 | 98.92 | 291.54 | 68.63 | −145.18 | 87.79 | 13.23 |
| Manousaridis and colleagues[ | 26,499,510 | 2016 | With ILM peel | 20 | 486 | 76 | 396 | 41 | −90 | 65.89 | 14.73 |
CFT, central foveal thickness; ILM, internal limiting membrane; PMID, PubMed IDentifier; TA, triamcinolone; BBG, brilliant blue G.
Figure 2.Results for preoperative–postoperative BCVA.
Figure 3.Results for preoperative-postoperative CFT.
Risk of bias – Newcastle Ottawa Scale.
| Study | Selection | Comparability | Exposure | Total NOS star rating | |||||
|---|---|---|---|---|---|---|---|---|---|
| Adequate definition of case | Representativeness of cases | Selection of controls | Definition of controls | Comparability of cases and controls | Ascertainment of exposure | Same method of ascertainment for cases and controls | Non-response rate | ||
| Lim and colleagues[ |
|
|
|
| 4/9 | ||||
| Obata and colleagues[ |
|
|
|
|
|
|
|
| 9/9 |
| Deltour and colleagues[ |
|
|
|
| 4/9 | ||||
| Shimada and colleagues[ |
|
|
|
| 4/9 | ||||
| Kwok and colleagues[ |
|
|
|
|
|
|
|
| 9/9 |
| Mayer and colleagues[ |
|
|
|
| 4/9 | ||||
| Tari and colleagues[ |
|
|
|
| 4/9 | ||||
| Pournaras and colleagues[ |
|
|
|
|
|
|
|
| 9/9 |
| Lee and colleagues[ |
|
|
|
|
|
|
|
| 9/9 |
| Ahn and colleagues[ |
|
|
|
|
|
|
|
| 9/9 |
| Machado and colleagues[ |
|
|
|
| 4/9 | ||||
| Kumar and colleagues[ |
|
|
|
| 4/9 | ||||
| Manousaridis and colleagues[ |
|
|
|
| 4/9 | ||||
NOS: Newcastle Ottawa Scale
A study can be given a maximum of one star for each numbered item within the Selection and Outcome categories.
A maximum of two stars can be given for Comparability.
Cochrane Risk of Bias.
| Study | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other bias |
|---|---|---|---|---|---|---|---|
| Ripandelli and colleagues[ |
|
| − | ? |
|
|
|
| Tranos and colleagues[ |
|
| − |
|
|
|
|
| De Novelli and colleagues[ |
|
| − | ? |
|
|
|
: low risk of bias; –: high risk of bias, ?: unclear risk of bias.